Vera Therapeutics (VERA) Enterprise Value (2020 - 2026)

Vera Therapeutics has reported Enterprise Value for 7 years, with the latest figure at -$596.8 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 1.17% year-over-year to -$596.8 million; the trailing twelve-month figure through Mar 2026 stood at -$596.8 million (down 1.17% YoY), and the FY2025 full-year result was -$714.6 million, down 11.51% from the prior year.
• Enterprise Value for Q1 2026 stood at -$596.8 million, up from -$714.6 million in the prior quarter.
• The five-year high for Enterprise Value was -$114.4 million in Q3 2022, with the low at -$714.6 million in Q4 2025.
• Historically, Enterprise Value has averaged -$349.9 million across 5 years, with a median of -$353.3 million in 2024.
• Annual changes were most pronounced in 2024 — Enterprise Value tumbled 298.75% — and 2026, when it slipped 1.17%.
• Vera Therapeutics' Enterprise Value stood at -$114.7 million in 2022, then sank by 40.18% to -$160.7 million in 2023, then plunged by 298.75% to -$640.9 million in 2024, then decreased by 11.51% to -$714.6 million in 2025, then rose by 16.49% to -$596.8 million in 2026.
• The last three Enterprise Value figures came in at -$596.8 million (Q1 2026), -$714.6 million (Q4 2025), and -$497.4 million (Q3 2025), per Business Quant data.